日本化学療法学会雑誌第58巻第S-2号
|
|
|
- さや みつだ
- 7 years ago
- Views:
Transcription
1 μ Key words Streptococcus pneumoniae β Haemophilus influenzae β Moraxella Branhamella catarrhalis I
2 F F H C SO H H O H N N N N F CO H O Fig.1. Chemicalstructureoftosufloxacintosilatehydrate. α
3 Body weight (g) 1 Male Control mg/kg 1, mg/kg, mg/kg Female Body weight (g) Administration (day) Recovery (day) Fig.. ChangesinmeanbodyweightinjuvenileratsadministeredTFLXoralyfor1 month. :Thediferencefrom controlsissignificantatp<.inthe,mg/kggroup. Organ/Tissue andfindings Dose(mg/kg) Numberofanimals Kidney Crystal,renaltubularlumen Dilatation,renaltubule Foreignbodyreaction Table1. HistopathologyinjuvenileratsadministeredTFLXoralyfor1month 8M Control 8F 7M F 1M [+] [±] 1, 1F [±],1[+] [+] 1M, 1F [±],1[+] [±],[+] [±],1[+] [±],[+] [±] [±] Numberofanimalswithfindingsanddegreein[](±,veryslight;+,slight). M:male. F:female. Therewerenohistopathologicalfindingsrelatedtotestarticleadministrationinotherorgans/tissues,includingthebrain,pituitary,salivary gland,thymus,heart,lung,liver,spleen,adrenal,cecum,thyroid,testis,seminalvesicle,prostate,epididymis,ovary,uterus,trachea,pancreas, tongue,esophagus,stomach,smalintestine,largeintestine,submandibularlymphnode,mesentericlymphnode,eye,harderiangland,skele talmuscle,spinalcord,bone,bonemarow,vagina,mammarygland,urinarybladder,skin,andaorta. Therewerenohistopathologicalfindingsrelatedtotestarticleadministrationattheendofrecoveryinthe,mg/kggroup.
4 Day 7, Male Body weight (kg) 1 C TFLX NFLX CPFX (mg/kg) Day 7, Female Body weight (kg) 1 C 1 6 TFLX (mg/kg) Fig.. BodyweightinjuveniledogsadministeredTFLX,NFLX,andCPFXfor1 month. Individual( )andgroupmean( )bodyweightsontheendofadministra tion(day7)areindicated. Erorbarsarestandarddeviation. μ μ μ Ω
5 Table. HistopathologyinjuveniledogsadministeredTFLXoralyfor1month Organ/Tissue Testsubstance TFLX NFLX CPFX Control andfindings Dose(mg/kg) Numberofanimals Bonemarow,sternal Decrease,hematopoieticcel Bonemarow,femoral Decrease,hematopoieticcel Spleen Decrease,lymphocyte,whitepulp Thymus Decrease,lymphocyte Liver Atrophy/decreasedglycogen area,hepatocyte Bone,sternum Retardedossification, trabecula,spongybone Bone,femur Retardedossification, trabecula,spongybone F F F [±] F [±,++] [±,++] [±,+] Numberofanimalswithfindingsanddegreein[](±,veryslight;+,slight;++,moderate). M:male. F:female. Therewerenochangesrelatedtotestarticleadministrationinanygroupsinotherorgans/tissues,includingthebrain,pituitary,submandibu largland,heart,lung,galbladder,pancreas,kidney,adrenal,thyroid,testis,prostate,epididymis,ovary,uterus,trachea,tongue,stomach, smalintestine,largeintestine,submandibularlymphnode,mesentericlymphnode,eye,lacrimalgland,skeletalmuscle,spinalcord,sciatic nerve,vagina,mammarygland,urinarybladder,skin,aorta,andarticularcartilageofshoulder,elbow,carpal,hip,knee,andtarsaljoint. Therewerenohistopathologicalfindingsrelatedtotestarticleadministrationattheendofrecoveryinthe6mg/kggroup. [±] [±] 1[+] 1[+] II
6 1 Male Female Plasma level of tosufloxacin ( µ g/ml) Time after administration (h) Time after administration (h) Fig.. PlasmalevelofTFLXafteroraladministrationinjuveniledogs. Onthefinalday(Day8)ofdosingat1( ),( ),and6mg/kg( ). Erorbarsarestandarddeviation. μ μ μ μ μ μ
7 Table. Grosspathologyofarticularcartilageandtoxicokineticparametersinjuvenile dogs(-month-old)administeredtflxforweeks Dose(mg/kg) Numberofanimals Control Grosspathology(numberofanimalswithfindings) Shoulderjoint Humerus,proximal Blister Erosion Elbowjoint Humerus,distal Ulna/Radius,proximal Carpaljoint Ulna/Radius,distal Hipjoint Femur,proximal Kneejoint Femur,distal Tibia,proximal Tarsaljoint Tibia/Fibula,distal 1[+] 1[+] [+] Toxicokineticparameters 1stadministration Cmax(μg/mL) AUC-t(μg h/ml) 1thadministration Cmax(μg/mL) AUC-t(μg h/ml) []:Degreeoffindings(+,slight). Table. Histopathologyofarticularcartilageinjuveniledogs(-month-old)administeredTFLX forweeks Siteandfindings Dose(mg/kg) Numberofanimals Shoulderjoint Humerus,proximal Cavitation Detachment,cartilagesurfacelayer Necrosis,chondrocyte Clusterformation,chondrocyte Fibrosis Hipjoint Femur,proximal Kneejoint Femur,distal Control 1[++] 1[++] 1[++] 1[+] Numberofanimalswithfindingsanddegreein[](+,slight;++,moderate). NE:notexamined. NE NE 1[+] 1[+],1[++] [+],1[++] [+],1[++] III
8 Table. IncidenceofarthropathyandtoxicokineticparametersinjuveniledogsadministeredNFLXandCPFXfor1 week Drug Animal Dose(mg/kg) Numberofanimals NFLX Beagle,--month-old NFLX CPFX Beagle,--month-old F F Numberofanimalswitharthropathy Total Shoulderjoint Elbowjoint Carpaljoint Hipjoint Kneejoint Tarsaljoint Toxicokineticsparameters 1stadministration Cmax(μg/mL) AUC-inf(μg h/ml) 6thadministration Cmax(μg/mL) AUC-inf(μg h/ml) Reference M:male. F:female..±.78.11± ±7.1 1.±1.1 6.±. 9.6±9.7 Machida,etal(199) 16) M.±. M.6±.6 F.19±.9 F.9±1.1 M.±1.8 M.8±11.8 F.±16.1 F.9±9.9 M.±1. M.±.79 F1.7±1.1 F6.±1. M 11.9±.7 M.9±9. F1.1±8.8 F.±1.9 Nagai,etal() 17) μ μ
9 1 11 Mean blood pressure 1 1 Heart rate 7 QTc (mmhg) (beat/min) 8 6 (msec) Time after administration (h) 1 1 Fig.. EfectofTFLXonthecardiovascularparameterindogs. Bloodpressure,heartrate,andECGweremonitoredbytelemetryafterasingleoraldoseofTFLXat ( ),( ),and1( )mg/kg. Table6. TFLXandMFLXefectsonhERGcurentstablyexpressedHEK9cels Testsubstance Concentration (μmol/l) Numberof preparations %before a %inhibition Vehicle b 9.9± 1.9 TFLX ± ± ±.6 9.6± MFLX 1 1 a :percentageofvaluejustbeforeapplication. b :.vol%dimethylsulfoxide. Eachvaluerepresentsmean±S.E. :Significantdiferencefrom controlatp<.. 87.± ±. 6.± μ μ μ μ
10 1 Glucose, Insulin 1, 1 (mg/dl) (pg/ml) 1, Time after administration (h) Time after administration (h) Fig.6. EfectofTFLXonglucoseandinsulinlevelsinserum indogsafterasingleoraldoseof TFLXat( ),1( ),6( )mg/kg,andtolbutamide1,mg/body( ). :Significantdiferencefrom controlatp<.. μ μ μ μ μ β β in vitro μ μ μ β in vitro
11 In vitro in vivo Chlamydia Streptococcus pneumoniae in vitro β Haemophilus influenzae Haemophilus influenzae In
12 μ
日本化学療法学会雑誌第59巻第5号
Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S.
日本化学療法学会雑誌第57巻第5号
in vitro Key words Streptococcus pneumoniae β Haemophilus influenzae Escherichia coli I Table. Antibacteriallevofloxacinactivityagainstclinicalisolates Organism Year Susceptibility(%)(Numberofstrains)
日本化学療法学会雑誌第57巻第6号
Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae S. pneumoniae β β H. influenzae S. pneumoniae H. influenzae M. catarrhalis Key words Otalgia Fever Item Crying,Iritation,
日本化学療法学会雑誌第61巻第6号
β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae
日本化学療法学会雑誌第55巻第S-1号
µ µ Key words Streptococcus pneu- moniae S. pneumoniae µ µ I γ H H C HN F F O N O CO H H C SO H H O Fig.. ChemicalstructureofGRNX. γ γ II Haemophilus influenzae Pseudomonas aeruginosa Streptococcus intermedius
日本化学療法学会雑誌第54巻第S-1号
β β β Key words β β I HP- -CD CHR RHC R R R R CHR R R R R RHC R R R CHR R R R RHC CHR R H CH CH Fig.. Structuralformulaofhydroxypropyl-β -cyclodextrin(hp-β -CD). CH n H β β β β Table-. Dosageandadministration(Singleadministrationstudy)
一般演題（ポスター）
6 5 13 : 00 14 : 00 A μ 13 : 00 14 : 00 A β β β 13 : 00 14 : 00 A 13 : 00 14 : 00 A 13 : 00 14 : 00 A β 13 : 00 14 : 00 A β 13 : 00 14 : 00 A 13 : 00 14 : 00 A β 13 : 00 14 : 00 A 13 : 00 14 : 00 A
日本化学療法学会雑誌第56巻第1号
β β β β β Streptococcus pneumoniaehaemophilus influenzaemoraxella catarrhalismycoplasma pneumoniaechlamydia pneumoniae β Key wordsβ mys nilc laci ngis Table. Assessmentschedule Parameters Patientcharacteristics
日本化学療法学会雑誌第56巻第S-1号
Key words Streptococcus pneumoniae µ µ H F Cl H H N N H N F COOH O Fig.1. Sitafloxacinstructure. I γ S. pneumoniae Haemophilus influenzae Table1. Observationandtestschedule Observation/Tests Informedconsent
日本化学療法学会雑誌第57巻第1号
In vitro Streptococcus pneumoniae Escherichia coli in vitro Streptococcus pneumoniae Escherichia coli µs. pneumoniae E. coli µ Key words in vitrostreptococcus pneumoniae Escherichia coli Escherichia coli
日本化学療法学会雑誌第65巻第4号
Mycoplasma pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae Key words Mycoplasma pneumoniae Mycoplasma pneumoniae M. pneumoniae I M. pneumoniae M. pneumoniae M. pneumoniae
CHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
Feb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 53 53 Tebipenem pivoxil 1 1, 3 2 2 1 1 Meiji Seika 2 Meiji Seika G 3 Meiji Seika 2015 12 15 Tebipenem pivoxil 10% 2010 4 2013 3 3,547 3,540 3,540 3,331
1 913 10301200 A B C D E F G H J K L M 1A1030 10 : 45 1A1045 11 : 00 1A1100 11 : 15 1A1115 11 : 30 1A1130 11 : 45 1A1145 12 : 00 1B1030 1B1045 1C1030
1 913 9001030 A B C D E F G H J K L M 9:00 1A0900 9:15 1A0915 9:30 1A0930 9:45 1A0945 10 : 00 1A1000 10 : 15 1B0900 1B0915 1B0930 1B0945 1B1000 1C0900 1C0915 1D0915 1C0930 1C0945 1C1000 1D0930 1D0945 1D1000
VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega
1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity
日本糖尿病学会誌第58巻第1号
α β β β β β β α α β α β α l l α l μ l β l α β β Wfs1 β β l l l l μ l l μ μ l μ l Δ l μ μ l μ l l ll l l l l l l l l μ l l l l μ μ l l l l μ l l l l l l l l l l μ l l l μ l μ l l l l l l l l l μ l l l l
診療ガイドライン外来編２０１４（Ａ４）／ＦＵＪＧＧ２０１４‐０１（大扉）
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
日本糖尿病学会誌第58巻第3号
l l μ l l l l l μ l l l l μ l l l l μ l l l l l l l l l l l l l μ l l l l μ Δ l l l μ Δ μ l l l l μ l l μ l l l l l l l l μ l l l l l μ l l l l l l l l μ l μ l l l l l l l l l l l l μ l l l l β l l l μ
CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
日本化学療法学会雑誌第60巻第4号
Streptococcus pneumoniae Haemophilus influenzae S. pneumoniae H. influenzae Key words β Streptococcus pneumoniae Haemophilus influenzae S. pneumoniae H. influenzae μ μ S. pneumoniae H. influenzae S. pneumoniae
CHEMOTHERAPY SEPT. 1991
CHEMOTHERAPY SEPT. 1991 VOL. 39 S-3 Table 1. Background of characteristics and allocation of 9 healthy male volunteers in a single-dose study on betamipron Table 2. Background of characteristics and allocation
日本化学療法学会雑誌第64巻第4号
β β Moraxella catarrhalisescherichia colicitrobacter Klebsiella pneumoniaeenterobacter cloacaeserratia marcescens Proteus Providencia Pseudomonas aeruginosaacinetobacter Bacteroides fragilis β β E. colik.
THE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 June 2014 STFX mg mg mg mg mg 1
June 2014 THE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 175 29 1 2 2 2 2 2 3 4 4 5 5 2 2 1 2 3 4 5 2014 4 15 STFX 50 mg 10% 2011 8 1 100 mg 1 1 2011 12 2013 5 226 1,186 1,089 1,069 2.11% 23/1,089 1.10% 12/1,089
立命館21_松本先生.indd
2143-552010 1 2 () 1 2 3 456 78- Key Words 1 3 12007 2 3 508 19992008 1 23 4 43 2120107 4 2008 1992 2003 2005 1989 2008 4 2 2-1 10 4 4 6 5 4 5 2946 1 155 11 41 44 45 4 2-2 2003 1 21 2 1 3 4 5 6 7 3 2120107
立命館20_服部先生.indd
20 93-105 2010 2 () ' - 1 ( ) ( ' 2005) Key Words 2 1967 93 20 2010 1 94 1 ' 2002 2 2 1996 1996 1999 2 2 2 1993 1999 4 1 2 1985 1989 1986 1994 4 1 2 1 1 4 2 4 4 1 4 1966 4 10-1970 20 1993-1972 95 20 2010
1996 2000 2004 1984 2005 7150 000 9 500 9 4 13 10 95 11 11 12 20002004 9 70
14 2006 1 Key Words 2002 3 1 2 3 3 1 2 3 1969 1987 69 1996 2000 2004 1984 2005 7150 000 9 500 9 4 13 10 95 11 11 12 20002004 9 70 14 2006 1 15 71 72 1 22 6 32 9 200 6 3 1 2 2000 10 1 2003 10 2005 6 5 4
立命館16_坂下.indd
1669-792008 1 - ' 85- -108 ' Key words 1 2 2003 69 1620082 5 3 1990 1997 4 5 2001 1307 6 7 1 1 1 1996 100 2 1997 71 3 1998 71 4 1999 96 5 2000 95 6 2001 145 7 2002 191 8 2003 174 9 2004 120 10 2005 122
立命館人間科学研究No.10
1 77 5 Key words 1 23 3 11417 14310045 20022004 2 2003 20022005 20022004 2 10200511 3 2003 1152003 59 1995 3 32003 19932002 20032003 2005 20052005 4 1997 2000521986 2001 42001 3 1981 6 1 7 5 1000248 1632647
立命館21_川端先生.indd
21 119-132 2010 ( ) ' Key Words 119 21 2010 7 1962 2001 2001 2007 1982 1988 1997 2007 1997 1998 1863 1880 1 1998 1998 2001 1599 120 121 1599 1695 8 1695 1714 4 1714 1715 5 1715 100 1812 9 1812 1864 2001
立命館14_前田.indd
1499-1122007 1 ) ) ) ) ) (1) -- ) ) ) ) ) ) ( ) ) ' ) ) ) ) - 1) 2)' 3) Key words 19811994 1721 99 1420073 100 20012004 2005 2004 2002 33 34 10 1987 45 20002003 2002 1 1 2000 1 1 2001 2 200341 12004 2
立命館17_坂下.indd
1793-1052008 1 () -- -- - Key words 1 93 1720088 2 3 2003 15 1996 50 3040 2 3 4050 50 10 1980 1995 1950 1958 1968 1972 94 95 1987 4 4 70 3 3 1 2000 2001 4 1720088 96 2001 2003 2 1978 1990 1997 130 2 3
立命館人間科学研究No.10
49 00 7 Key words 980 995 50 0005 90 997 99 990 994 99 99 99990 99 996 988988 994 99 995 995 995 994 984 988 986 997 997 00 995 00 5 7 5 5 999 997 997 998 6 998 999 997 997 998 0040000 994 996 000 00 5
立命館19_椎原他.indd
191-132009 1 ( ) ' Key Words 1 11 12007 2007 200520062 201120062 7558 4009 1 1920098 2007 2 2000 028 2005 1999 12 1999 13 1968 2 3 '1992 2007 2001 20052001 1977 2005 2005 2007 21 21 22 461927 3 13 1920098
立命館人間科学研究No.10
61 10 1990 Key words 1 102005 11 62 2000 1 1920 10 1892 63 1 1 19 100 1914 100 1 1 20 1 2 102005 11 64 1946 21 4 1947 1949 1947 22 1 3 1956 1959 1958 2 1964 65 2 10 1975 7080 70 2 1 1987 1990 40 1989 1989
立命館19_徳田.indd
1991-1022009 1 2 () )--) 28 2827 1 2 Key Words 1 (1721 2000 20012001 20082009 91 1920098 92 20042004 2004 2001 12 2005 20082009 2005 3 1997 200820096 2007 2 20082009 93 20012001 12 2008 2009 19611966 1
日本化学療法学会雑誌第51巻第2号
piperacillin piperacillin PIPC. g Cmax CL PIPC CL CLR CLNR CL PIPC g g Cmax PIPC Key words: piperacillin Piperacillin PIPC PIPC g g PIPC Cmax g g ml g g ml g g ml T T T PIPC g g T Ccr ml min AUCCmax PIPC
日本糖尿病学会誌第58巻第2号
β γ Δ Δ β β β l l l l μ l l μ l l l l α l l l ω l Δ l l Δ Δ l l l l l l l l l l l l l l α α α α l l l l l l l l l l l μ l l μ l μ l l μ l l μ l l l μ l l l l l l l μ l β l l μ l l l l α l l μ l l
日本化学療法学会雑誌第57巻第S-2号
µ µ Key words µ µ µ I Table1. Subjectprofilesin(A)singleand(B)multiple-dosestudies (A)Single-dosestudy Age (yr) Height (cm) Bodyweight (kg) BMI (kg/m ) Ccr(Cockcroft) (ml/min) Ethnicity dose(mg) n 5 5.1±.,3
日本化学療法学会雑誌第57巻第4号
Streptococcus pneumoniae Haemophilus influenzae β β Key words I β Enterococcus faecium Pseudomonas aeruginosa Streptococcus pneumoniae S. pneumoniae Haemophilus influenzae S. pneumoniae H. influenzae Table.
20 15 14.6 15.3 14.9 15.7 16.0 15.7 13.4 14.5 13.7 14.2 10 10 13 16 19 22 1 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 2,500 59,862 56,384 2,000 42,662 44,211 40,639 37,323 1,500 33,408 34,472
I? 3 1 3 1.1?................................. 3 1.2?............................... 3 1.3!................................... 3 2 4 2.1........................................ 4 2.2.......................................
- 2 -
- 2 - - 3 - (1) (2) (3) (1) - 4 - ~ - 5 - (2) - 6 - (1) (1) - 7 - - 8 - (i) (ii) (iii) (ii) (iii) (ii) 10 - 9 - (3) - 10 - (3) - 11 - - 12 - (1) - 13 - - 14 - (2) - 15 - - 16 - (3) - 17 - - 18 - (4) -
2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1
1 1979 6 24 3 4 4 4 4 3 4 4 2 3 4 4 6 0 0 6 2 4 4 4 3 0 0 3 3 3 4 3 2 4 3? 4 3 4 3 4 4 4 4 3 3 4 4 4 4 2 1 1 2 15 4 4 15 0 1 2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4
1 (1) (2)
1 2 (1) (2) (3) 3-78 - 1 (1) (2) - 79 - i) ii) iii) (3) (4) (5) (6) - 80 - (7) (8) (9) (10) 2 (1) (2) (3) (4) i) - 81 - ii) (a) (b) 3 (1) (2) - 82 - - 83 - - 84 - - 85 - - 86 - (1) (2) (3) (4) (5) (6)
VOL.39 S-3
VOL.39 S-3 CHEMOTHERAPY SEPT.1991 Table 1. Background of characteristics and allocation of 5 healthy male volunteers in a multiple-dose study on panipenem/betamipron Day 1 Fig. 1. Schedule of multiple-dose
第89回日本感染症学会学術講演会後抄録（I）
! ! ! β !!!!!!!!!!! !!! !!! μ! μ! !!! β! β !! β! β β μ! μ! μ! μ! β β β β β β μ! μ! μ!! β ! β ! ! β β ! !! ! !!! ! ! ! β! !!!!! !! !!!!!!!!! μ! β !!!! β β! !!!!!!!!! !! β β β β β β β β !!
2 TBARS
1 - AsA) ) ( ODS AsA TOC ODS ODS ODS PQ 2 TBARS 3 1) 2) 4 5 ODS PQ 250mg/ PQ 125mg/ PQ 125mg/ PQ PQ 125mg/ Mg ODS Mg 25g Mg Na Ca ATP Mg ODS Mg PQ 6 Mg ODS Mg PQ Mg Mg 7 Table 1 Composition of basal diet
日本化学療法学会雑誌第54巻第S-1号
β β Key words β Candida krusei Candida glabrata β I β Drugadministration Baselinecharacteristics Clinicalsymptom Mycologicaltests Plasmadrugconcn Adverseevents Laboratorytests ) -leadecg Clinicalphotograph
CHEMOTHERAPY APR. 1982
VOL.30 S-1 CHEMOTHERAPY Table 1 Dose of CTT and subjects i. v.: Intravenous bolus injection d. i. v.: Intravenous drip infusion i. m.: Intramuscular injection Fig. 1 Schedule for examination of CTT, 1.0g
MultiWriter 5600C 活用マニュアル
1 *1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8 9 9 1 2 3 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 1 2 3 a b c 26 27 28 C *1 *2 *2 29 2 2 2 2 2 2 2 2 2 30 *1 *2 ± *1 C C 31 32 33 34 35 36 M C Y K 1 2 3 4 5 6
日本化学療法学会雑誌第55巻第S-1号
Key words I γ II Table. FertilitydataonmaleratstreatedoralywithGRNXinthestudyoffertilityandearlyembryonic developmenttoimplantation No.ofmaleratsexamined Copulationrate(%) Impregnationrate(%) No.ofsperms(
VOL. 20 NO. 5 CHEMOTHERAPY Methoxy-4-sulfanilamidopyrimidine (OS-3376) Sulfadimethoxine (SDM) Table 1. In vitro antibacterial activities of OS-3
VOL. 20 NO. 5 CHEMOTHERAPY 653 2-Methoxy-4-sulfanilamidopyrimidine (OS-3376) Sulfadimethoxine (SDM) Table 1. In vitro antibacterial activities of OS-3376, SDM, SIZ and SMZ against Gram-positive and negative
untitled
COLAK Mehmed 11000 305 305 180 10000 9000 8000 160 140 120 7000 100 6000 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 80 GH IGF-1 GH GH 5 4 3 2 1 0 2 3 4 5
untitled
ORYZA OIL & FAT CHEMICAL CO., LTD. WHITE JELLY FUNGUS EXTRACT -P () Ver. 1.3SJ Ver. 1.3SJ 1. 3000 ph 1 Ver. 1.3SJ 1. 1 2. 3 2-1. 2-2. 2-3. 2-4. SOD 3. 7 3-1. in vitro 3-2. in vivo 3-3. in vivo 3-4. in
Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-
Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl) oxy]-14-ethyl-12,